PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PYPDPETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PYPD(NASDAQ:PYPD) PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PYPD(NASDAQ:PYPD) PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025.
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PYPDPolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal surgery vs. standard care.
HC Wainwright & Co. Maintains Buy on PolyPid, Raises Price Target to $13
PYPDPolypid Announces Results From SHIELD II Phase 3 Trial Of D-PLEX100 For Preventing SSIs In Abdominal Colorectal Surgery Patients With Large Incisions
PYPDPolyPid's Surgery Drug Cuts Infection Risk by 38% in Major Phase 3 Trial
PYPDPolyPid Will Host A Conference Call And Webcast To Report Topline Data For The SHIELD II Phase 3 Trial, Evaluating D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery, On Monday, June 9, At 8:30 a.m
PYPDRoth Capital Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $9
PYPDHC Wainwright & Co. Assumes PolyPid at Buy, Announces Price Target of $11
PYPDPolyPid Had Cash And Cash Equivalents And Short-term Deposits Of $8M, As of March 31, 2025, That Is Expected To Provide Cash Runway Into Q3 Of 2025
PYPDPolyPid Q1 2025 EPS $(0.70) Beats $(0.80) Estimate
PYPDA Look Ahead: PolyPid's Earnings Forecast
PYPDHC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $11 Price Target
PYPDPolyPid Wraps Up Phase 3 Enrollment For D-PLEX100, Eyes FDA Submission Following Q2 Top-Line Data
PYPDPolyPid Q4 2024 GAAP EPS $(1.13) Misses $(0.82) Estimate; Cash $15.6M
PYPDReported Earlier, PolyPid's SHIELD II Trial Receives DSMB Recommendation To Continue Enrollment To 800 Patients
PYPDCraig-Hallum Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $10
PYPDPolyPid Earlier Announces Presentation Of Phase 2 D-PLEX₁₀₀ Clinical Data At The European Society For Coloproctology Scientific Conference Sept 21-23
PYPD